Welcome to our dedicated page for Viemed Healthcare news (Ticker: VMD), a resource for investors and traders seeking the latest updates and insights on Viemed Healthcare stock.
The Viemed Healthcare, Inc. (VMD) news page on Stock Titan aggregates company-specific updates for investors and observers who follow in-home post-acute respiratory care and home medical equipment providers. Viemed’s public communications describe it as a national leader in technology-enabled, in-home clinical care focused on non-invasive ventilation and related respiratory therapies in the United States.
News items for Viemed commonly include quarterly and year-to-date financial results, where the company reports revenue, net income, adjusted EBITDA, cash flow, and balance sheet data. These earnings releases, often furnished to the SEC on Form 8-K, are accompanied by financial supplements and sometimes updated full-year guidance ranges. They also highlight trends in ventilator, PAP therapy, and sleep resupply patient counts, as well as commentary from management on operating performance.
Another important category of news involves strategic transactions and capital allocation. Recent press releases have covered the authorization and completion of a share repurchase program, including the total number of shares repurchased and aggregate purchase price. Viemed has also announced the completion of its acquisition of Lehan’s Medical Equipment, an Illinois-based provider of home medical equipment with a focus on women’s health products and respiratory devices, and has discussed how this acquisition fits within its broader platform.
Visitors to this page can also expect updates about credit facility amendments, investor presentations, and conference appearances, which are often disclosed through Form 8-K filings and press releases. Together, these news items provide a view into Viemed’s operating trends, service diversification, financing arrangements, and outreach to the investment community. For anyone tracking VMD, this page serves as a centralized feed of the company’s official announcements and related coverage.
Viemed Healthcare (NASDAQ:VMD) will present and host one-on-one investor meetings at Sidoti's Small-Cap Virtual Investor Conference on March 18-19, 2026. The company presentation is scheduled for 1:45 p.m. ET on March 19, 2026. Registration is free and open online.
Investors can access the live presentation via Sidoti's webinar link and sign up for virtual one-on-ones on March 18-19, 2026.
Viemed Healthcare (NASDAQ: VMD) reported FY25 results showing net revenue of $270.3M (up 21% y/y), net income $14.9M, and record adjusted EBITDA $61.4M. Free cash flow rose 141% y/y. Growth was driven by platform momentum, contributions from Lehan's, and stronger sleep/resupply adoption. A revised NCD added documentation and tightened coverage criteria, temporarily moderating ventilator patient growth, though reimbursement levels were unchanged and vent activity began normalizing. Management and coverage updates indicate sleep and resupply are improving recurring revenue quality and diversification of payors, while FY26 guidance and valuation suggest upside may be underappreciated.
Viemed Healthcare (NASDAQ:VMD) announced a share repurchase program effective through March 2027 authorizing purchases of up to 1,930,131 common shares, about 5% of issued shares as of March 4, 2026. Purchases may occur via open market or block trades and repurchased shares will be cancelled.
The company highlighted prior repurchases of ~4.5 million shares totaling $26.3 million, record 2025 revenue and Adjusted EBITDA, more than doubled free cash flow year-over-year, $13.5 million cash at year-end, and effectively no net debt.
Viemed Healthcare (NASDAQ:VMD) reported record 2025 results and issued 2026 guidance on March 4, 2026. Q4 net revenue was $76.2M (+26% YoY) and FY revenue was $270.3M (+21% YoY). FY net income was $14.9M ($0.37/diluted), Adjusted EBITDA a record $61.4M.
The company generated $51.9M cash from operations and $28.1M free cash flow in 2025, maintained $13.5M cash and $7.4M working capital, and had $46M available on its credit facility. 2026 guidance: revenue $310–320M, Adjusted EBITDA $65–69M, capex 10–11.5% of revenue. Board authorized a 2026 share repurchase program.
Viemed Healthcare (NASDAQ:VMD) will host its Year End 2025 earnings conference call on Thursday, March 5, 2026 at 11:00 a.m. ET. Interested parties may dial US Toll-Free or international numbers or join via live audio webcast.
A replay will be available in the Investor Relations section of the company website at www.viemed.com after the live call.
Stonegate Capital Partners initiated coverage on Viemed Healthcare (NASDAQ: VMD) on January 6, 2026.
Viemed is described as a leading U.S. provider of in-home post-acute respiratory care focused on non-invasive ventilation (NIV) for COPD and chronic respiratory failure, operating a clinician-driven model with respiratory therapists, proprietary workflows, and continuous monitoring.
Key disclosed metrics include 15 consecutive quarters of organic growth and management guidance implying approximately 20% year-over-year revenue growth and about 22% EBITDA margins. The firm has diversified into sleep therapy and resupply, oxygen therapy, staffing, and maternity care to broaden its platform.
Viemed Healthcare (NASDAQ:VMD) reported third quarter 2025 results for the three and nine months ended September 30, 2025. Q3 net revenue reached a company record of $71.9M, up 24.0% year-over-year. Net income for Q3 was $3.5M or $0.09 per diluted share. Adjusted EBITDA totaled $16.1M, a 15.5% increase versus prior year.
Cash flow: operating cash flow was $18.4M for the quarter and $48.5M TTM; free cash flow was $12.4M for the quarter and $23.3M TTM.
Corporate actions: closed acquisition of Lehan's Medical Equipment on July 1, 2025; repurchased 1,706,380 shares for $11.4M. Balance sheet: cash $11.1M, working capital $5.8M, long-term debt $19.6M. 2025 guidance updated to $271M–$273M revenue and $60M–$62M adjusted EBITDA.
Viemed Healthcare (NASDAQ:VMD) will host its Third Quarter 2025 Earnings Conference Call on Thursday, November 6, 2025 at 11:00 a.m. ET. Participants can join by phone at (877) 407-6176 (US toll-free) or +1 (201) 689-8451 (international), or via live audio webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=asCOlSnC. A replay will be available in the Investor Relations section of Viemed's website at https://www.viemed.com. The call covers Viemed's Q3 2025 results and related commentary for investors and analysts.
Viemed Healthcare (NASDAQ: VMD) will present at the LD Micro Main Event XIX on Tuesday, October 21, 2025 at 11:00 AM PT at Hotel del Coronado in San Diego. Trae Fitzgerald, chief financial officer, will cover operational priorities, financial performance, and strategic direction. Management will be available for one-on-one investor meetings during the three-day conference.
The Main Event runs October 19–21, 2025, features roughly 120 companies presenting in half-hour slots, and includes keynotes, private investor meetings, and a closing reception. Investors can register to watch Viemed's virtual presentation.
Viemed Healthcare (NASDAQ:VMD), a leader in home-based post-acute respiratory care, has completed its share repurchase program announced on June 9, 2025. The company successfully repurchased and cancelled all 1,976,441 authorized common shares, representing approximately 5% of total outstanding shares.
The repurchase was executed at a weighted average price of $6.69 per share, totaling approximately $13.2 million. CEO Casey Hoyt emphasized that this program completion reflects the company's confidence in its long-term outlook and commitment to shareholder value, supported by strong balance sheet and increasing free cash flow.